Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: Richard Haugland who wrote (184)	4/21/1998 6:24:00 AM
From: Richard Haugland	Read Replies (1) \| Respond to of 3044

Millennium Pharmaceuticals, Inc. Awarded Composition of Matter Patent For UCPH Gene Second U.S. Patent Related To UCPH Awarded To The Company biz.yahoo.com UCPH protein, which is produced in mitochondria, burns excess calories consumed by uncoupling oxidative phosphorylation. The uncoupling process results in excess calories being converted into heat rather than being stored as fat. Therefore, UCPH influences energy expenditure. ''We believe that the UCPH gene is an important discovery in that it helps provide an explanation for why some obese people are not over-eaters, but are obese due to an inability to produce enough UCPH,'' said Robert Tepper, M.D., chief scientific officer, pharmaceuticals at Millennium. ''Unlike other obesity genes identified to date, UCPH is involved in regulating energy expenditure or the 'burning of calories.' With our partner Hoffmann-La Roche, we are currently evaluating using UCPH to discover small molecule drugs that may result in weight loss by speeding-up a person's metabolism.'' It would be positive for the company if this news, which was released at 6 AM ET, would be picked up by the public press wire services. Certainly should not hurt with the business press too, even though it is a LONG way from here to profits.